<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210288</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 2004.20</org_study_id>
    <nct_id>NCT00210288</nct_id>
  </id_info>
  <brief_title>Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine</brief_title>
  <official_title>A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Pasteur</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the immune response produced by two doses of SC599
      vaccine compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response assessed by the proportion of Immunoglobulin A (IgA) anti-Lipopolysaccharide (LPS) Antibody-Secreting Cells (ASC) responders.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Immune Response:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of volunteers who have a B subunit antibody response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of volunteers who have a LPS response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2) SC599 Shedding</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Proportion of volunteers who will excrete the vaccine strain and by the duration of the SC5999 shedding, defined as the time (days) between the first an last stool that were positive for SC599.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) Safety Assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-The safety will be evaluated by the proportions of clinical and biological adverse events. Illness after vaccination will be defined as either diarrhoea or fever.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Shigella Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SC599</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult volunteers age 18 to 50

          -  Signed Informed Consent form following a detailed written explanation of participation
             in the protocol

          -  Volunteers who are in good health as determined by medical history, physical
             examination and clinical judgement

          -  Volunteers who will be available and &quot;normally reside within the M25&quot; (England) or in
             Paris and Paris suburb (France) and not leave England or France for the duration of
             the study

          -  Women who agree to have a pregnancy test immediately before immunisation and to use
             effective contraception during the study period

          -  Volunteers eligible for free NHI treatment (England), volunteers who are covered by
             social security (France)

        Exclusion Criteria:

          -  Individuals who have hypersensitivity to any component of the vaccines used in this
             study.

          -  Individuals who have hypersensitivity to ciprofloxacin

          -  Individuals who are found to be HIV or HCV antibody positive or Hepatitis B surface
             antigen positive at the time of initial screening

          -  Individuals who are found to have HLA-B27 tissue type at the time of initial screening

          -  Individuals with a known or suspected history of gastrointestinal disease or
             abnormality

          -  Concomitant therapy with antibiotics, iron, zinc, H2-receptor antagonists or proton
             pump inhibitors

          -  Individuals who have received any vaccine against Shigella or had proven or suspected
             shigellosis (bloody diarrhoea with fever) within 6 months prior to study entry

          -  Individuals with a significant level of immunity against Shigella detected at the
             screening visit (defined as serum ELISA anti-LPS IgG antibody titre greater than 3
             S.D. above the mean background activity of a bank of healthy human sera)

          -  A Clinically significant amount of protein or haemoglobin in the urine sample at the
             screening visit

          -  A Clinically significant abnormality in the haematological or biochemical assays (an
             abnormal value will be defined by the ranges quoted in each centre) at the screening
             visit

          -  A positive Shigella stool culture at the screening visit

          -  Individuals with a known impairment of immune function or those receiving
             immunosuppressive therapy (including systemic corticosteroids). Inhaled or topical
             steroid preparation are not a non-inclusion criterion

          -  Individuals with acute infections (including fever &gt; 37.5°C oral temperature)at the
             time of immunisation or any chronic disease

          -  Women capable of becoming pregnant who do not agree to have pregnancy testing before
             immunisation, or who do not agree to take effective contraception during the study
             period

          -  Breastfeeding women

          -  Individuals with a current problem with substance abuse or with a history of substance
             abuse which in the opinion of the investigator, might interfere with participation in
             the study

          -  Individuals with any condition which, in the opinion of the investigator, might
             interfere with the evaluation with the study objectives

          -  Individuals who have received an investigational product within 30 days prior to entry

          -  Individuals who cannot read, speak fluent French or English according to the
             investigational site setting

          -  Individuals who are planning to leave England or France prior to the end of the study
             period or who are likely not to complete the study

          -  Individuals who have persons living with them who in the opinion of the investigator
             may be at risk of disease if exposed to the vaccine strain or whose occupation may
             bring them into contact with persons at risk of disease or who are food handlers by
             occupation

          -  Individuals with close household contact with child younger than 5 years or a person
             with immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Odile Launay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin - Bâtiment Modulaire, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr David Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's Hospital Vaccine Institute, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC de Vaccinologie Cochin Pasteur</name>
      <address>
        <city>75679 Paris Cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Cellular and Molecular Medicine, St George's Hospital Vaccine Institute</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Shigella</keyword>
  <keyword>Oral Vaccine</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Placebo</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

